Edition:
United States

Becton Dickinson and Co (BDX)

BDX on New York Consolidated

193.19USD
25 Sep 2017
Change (% chg)

$0.13 (+0.07%)
Prev Close
$193.06
Open
$192.91
Day's High
$193.62
Day's Low
$192.04
Volume
653,100
Avg. Vol
1,280,190
52-wk High
$206.63
52-wk Low
$161.29

Chart for

About

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $43,933.69
Shares Outstanding(Mil.): 227.57
Dividend: 0.73
Yield (%): 1.51

Financials

  Industry Sector
P/E (TTM): -- 31.44 16.08
EPS (TTM): -- -- --
ROI: -- 13.78 14.60
ROE: -- 16.62 14.03

BRIEF-Becton Dickinson and Co announces launch of platform for RNA expression analysis

* Becton Dickinson and Co - announces launch of BD rhapsody, a platform for RNA expression analysis

Sep 12 2017

BRIEF-BD announces extension of exchange offers and consent solicitations for C. R. Bard Inc notes

* BD announces extension of exchange offers and consent solicitations for C. R. Bard Inc notes

Aug 29 2017

BRIEF-Retractable Technologies says court dismissed co's case against Becton, Dickinson and Co​

* On August 17, judge issued court's final judgment regarding RTI's suit against Becton, Dickinson and Co​

Aug 18 2017

FDA probes possible Becton Dickinson link to faulty lead tests (Aug. 17)

(The August 17 story has been updated with a correct headline and first paragraph to show the FDA is still investigating blood tubes from Becton Dickinson and the tubes have not been ruled out yet)

Aug 18 2017

CORRECTED-FDA probes possible Becton Dickinson link to faulty lead tests (Aug. 17)

Aug 17 Blood collection tubes made by Becton Dickinson & Co that were used in conjunction with Magellan Diagnostics' lead-testing devices are still being investigated as a potential cause of inaccurate lead test results.

Aug 18 2017

BRIEF-FDA provides update on its investigation into inaccurate results from certain lead tests‍​

* U.S. FDA provides update on its investigation into inaccurate results from certain lead tests‍​

Aug 17 2017

BRIEF-C.R. Bard shareholders approve proposed merger with Becton Dickinson

* Bard shareholders approve proposed merger with becton, dickinson

Aug 08 2017

BRIEF-Becton Dickinson and Co reports Q3 loss per share $0.75

* Q3 revenue $3.035 billion versus I/B/E/s view $3.06 billion

Aug 03 2017

BRIEF-Becton Dickinson extends exchange for C. R. Bard, Inc. notes

* BD announces extension of exchange offers and consent solicitations for C. R. Bard, Inc. Notes

Aug 01 2017

BRIEF-BD receives FDA clearance for new immunological diagnostic system

* BD receives FDA 510(k) clearance for new immunological diagnostic system Source text for Eikon: Further company coverage:

Jul 19 2017

Earnings vs. Estimates